SP-624 (Forvisirvat)
Major Depressive Disorder
Phase 2Active
Key Facts
About Arrivo BioVentures
Arrivo BioVentures, founded in 2018 and based in Raleigh, NC, is a private biotech holding company with a portfolio of two clinical-stage drug candidates acquired through licensing and partnerships. The company leverages an experienced management team with a strong track record in fundraising and exits to advance novel therapies for major depressive disorder (SP-624) and predicted severe acute pancreatitis (RABI-767). Its strategy centers on in-licensing and developing disease-modifying therapies with new mechanisms of action for conditions with high unmet need.
View full company profileTherapeutic Areas
Other Major Depressive Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Accelerated Deep TMS Protocol | BrainsWay | FDA Cleared |
| ZURZUVAE (zuranolone) | Sage Therapeutics | Phase 3 |
| MDD Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| NMDAR Antagonist (GM-2505/Bretisilocin) | Gilgamesh Pharmaceuticals | Phase 2 |
| Neuroplastogen (GM-1020) | Gilgamesh Pharmaceuticals | Phase 2a |
| NA-901 | Biomed | Phase 2B/3 |
| NBS System for MDD | Nexstim | Approved |
| Major Depressive Disorder Studies | Noesis Pharma Clinical Trials | Phase 2-4 |
| Depression Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| Neurotyping Platform for MDD | Universal Brain | Development |
| CLE-100 | Clexio Biosciences | Phase 2 |
| Proliv™Rx | Neurolief | Phase 2 |